BioCryst Pharmaceuticals | BCRX - Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Chugai Pharma JPY 32.37B 3.32B 2026-09
Daiichi Sankyo JPY 237.75B 12.21B 2026-09
DBV Technologies USD 15.8M 2.4M 2026-09
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.16B 39M 2026-09
Glaxosmithkline GBP 2.38B 264M 2026-09
Incyte USD 364.27M 12.54M 2026-09
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Novavax USD 25.53M 1.34M 2025-12
PTC Therapeutics USD 80.63M 6.74M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
Ultragenyx Pharmaceutical USD 97M 9M 2026-09
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09